Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

K Brachmann

Showing results (31-40 of 50) with videos related to

Pageof 5
Sort By:
The EMBO Journal|November 15, 2001
hADA3 is required for p53 activityT Wang, T Kobayashi, R Takimoto, et al.
Carcinogenesis|July 25, 2006
Inactive full-length p53 mutants lacking dominant wild-type p53 inhibition highlight loss of heterozygosity as an important aspect of p53 status in human cancersLawrence R Dearth, Hua Qian, Ting Wang, et al.
Proceedings of the National Academy of Sciences of the United States of America|November 16, 2007
Species-specific endogenous retroviruses shape the transcriptional network of the human tumor suppressor protein p53Ting Wang, Jue Zeng, Craig B Lowe, et al.
Proceedings of the National Academy of Sciences of the United States of America|March 24, 2004
A global suppressor motif for p53 cancer mutantsTimothy E Baroni, Ting Wang, Hua Qian, et al.
Molecular Ecology|July 11, 2023
Whole-genome sequencing reveals fine-scale environment-associated divergence near the range limits of a temperate reef fishCameron M Nugent, Tony Kess, Matthew K Brachmann, et al.
Die Pharmazie|January 1, 1982
[Subacute and subchronic percutaneous tolerance testing (28-day and 90-day test) of epicutaneously applied dis-infectants as demonstrated by the example of peroxyethanoic acid (author's transl)]A Kramer, W Weuffen, M Bauer, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 29, 2017
A First-in-Human Phase I Study of the Anticancer Stem Cell Agent Ipafricept (OMP-54F28), a Decoy Receptor for Wnt Ligands, in Patients with Advanced Solid TumorsAntonio Jimeno, Michael Gordon, Rashmi Chugh, et al.
Nucleic Acids Research|December 19, 2007
Genome wide screens in yeast to identify potential binding sites and target genes of DNA-binding proteinsJue Zeng, Jizhou Yan, Ting Wang, et al.
Investigational New Drugs|March 8, 2014
A phase I study of the human monoclonal anti-NRP1 antibody MNRP1685A in patients with advanced solid tumorsColin D Weekes, Muralidhar Beeram, Anthony W Tolcher, et al.
Pharmaceutical Research|June 19, 2012
Anti-neuropilin-1 (MNRP1685A): unexpected pharmacokinetic differences across species, from preclinical models to humansYan Xin, Shuang Bai, Lisa A Damico-Beyer, et al.
Pageof 5

Showing results (31-40 of 50) with videos related to

Sort By:
Pageof 5
The EMBO Journal|November 15, 2001
hADA3 is required for p53 activityT Wang, T Kobayashi, R Takimoto, et al.
Carcinogenesis|July 25, 2006
Inactive full-length p53 mutants lacking dominant wild-type p53 inhibition highlight loss of heterozygosity as an important aspect of p53 status in human cancersLawrence R Dearth, Hua Qian, Ting Wang, et al.
Proceedings of the National Academy of Sciences of the United States of America|November 16, 2007
Species-specific endogenous retroviruses shape the transcriptional network of the human tumor suppressor protein p53Ting Wang, Jue Zeng, Craig B Lowe, et al.
Proceedings of the National Academy of Sciences of the United States of America|March 24, 2004
A global suppressor motif for p53 cancer mutantsTimothy E Baroni, Ting Wang, Hua Qian, et al.
Molecular Ecology|July 11, 2023
Whole-genome sequencing reveals fine-scale environment-associated divergence near the range limits of a temperate reef fishCameron M Nugent, Tony Kess, Matthew K Brachmann, et al.
Die Pharmazie|January 1, 1982
[Subacute and subchronic percutaneous tolerance testing (28-day and 90-day test) of epicutaneously applied dis-infectants as demonstrated by the example of peroxyethanoic acid (author's transl)]A Kramer, W Weuffen, M Bauer, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 29, 2017
A First-in-Human Phase I Study of the Anticancer Stem Cell Agent Ipafricept (OMP-54F28), a Decoy Receptor for Wnt Ligands, in Patients with Advanced Solid TumorsAntonio Jimeno, Michael Gordon, Rashmi Chugh, et al.
Nucleic Acids Research|December 19, 2007
Genome wide screens in yeast to identify potential binding sites and target genes of DNA-binding proteinsJue Zeng, Jizhou Yan, Ting Wang, et al.
Investigational New Drugs|March 8, 2014
A phase I study of the human monoclonal anti-NRP1 antibody MNRP1685A in patients with advanced solid tumorsColin D Weekes, Muralidhar Beeram, Anthony W Tolcher, et al.
Pharmaceutical Research|June 19, 2012
Anti-neuropilin-1 (MNRP1685A): unexpected pharmacokinetic differences across species, from preclinical models to humansYan Xin, Shuang Bai, Lisa A Damico-Beyer, et al.
Pageof 5